Javier Fernández‐Calvo

1.6k total citations
24 papers, 1.1k citations indexed

About

Javier Fernández‐Calvo is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Javier Fernández‐Calvo has authored 24 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Hematology, 10 papers in Molecular Biology and 10 papers in Genetics. Recurrent topics in Javier Fernández‐Calvo's work include Multiple Myeloma Research and Treatments (12 papers), Acute Myeloid Leukemia Research (9 papers) and Chronic Lymphocytic Leukemia Research (8 papers). Javier Fernández‐Calvo is often cited by papers focused on Multiple Myeloma Research and Treatments (12 papers), Acute Myeloid Leukemia Research (9 papers) and Chronic Lymphocytic Leukemia Research (8 papers). Javier Fernández‐Calvo collaborates with scholars based in Spain, Montserrat and Liberia. Javier Fernández‐Calvo's co-authors include Jesús F. San Miguel, Marcos González, Ramón García‐Sánz, Marı́a Jesús Moro, Josè Antonio Pérez-Simón, María Dolores Tabernero, Joan Bladé, Alberto Órfão, Júlia Almeida and Fernando Ramos and has published in prestigious journals such as Blood, International Journal of Cancer and British Journal of Haematology.

In The Last Decade

Javier Fernández‐Calvo

23 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Javier Fernández‐Calvo Spain 15 952 643 321 298 180 24 1.1k
Richard E. Helmer United States 6 851 0.9× 694 1.1× 269 0.8× 140 0.5× 188 1.0× 9 1.3k
Hakumei Oh Japan 8 849 0.9× 363 0.6× 221 0.7× 305 1.0× 213 1.2× 15 1.1k
Fen‐Yu Lee Taiwan 14 918 1.0× 578 0.9× 432 1.3× 155 0.5× 174 1.0× 20 1.2k
Kiyotaka Kashima Japan 8 992 1.0× 499 0.8× 386 1.2× 132 0.4× 274 1.5× 14 1.2k
Dieter K. Hossfeld Germany 14 746 0.8× 304 0.5× 234 0.7× 137 0.5× 366 2.0× 24 920
Sylvie Ramond France 13 402 0.4× 312 0.5× 287 0.9× 274 0.9× 140 0.8× 18 792
Joseph O. Moore United States 10 1.0k 1.1× 555 0.9× 368 1.1× 181 0.6× 350 1.9× 17 1.3k
Najla H. Al Ali United States 14 767 0.8× 257 0.4× 351 1.1× 140 0.5× 112 0.6× 84 906
JR Testa United States 15 1.0k 1.1× 541 0.8× 238 0.7× 104 0.3× 414 2.3× 27 1.3k
CM Rubin United States 15 847 0.9× 432 0.7× 228 0.7× 97 0.3× 376 2.1× 20 1.0k

Countries citing papers authored by Javier Fernández‐Calvo

Since Specialization
Citations

This map shows the geographic impact of Javier Fernández‐Calvo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Javier Fernández‐Calvo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Javier Fernández‐Calvo more than expected).

Fields of papers citing papers by Javier Fernández‐Calvo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Javier Fernández‐Calvo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Javier Fernández‐Calvo. The network helps show where Javier Fernández‐Calvo may publish in the future.

Co-authorship network of co-authors of Javier Fernández‐Calvo

This figure shows the co-authorship network connecting the top 25 collaborators of Javier Fernández‐Calvo. A scholar is included among the top collaborators of Javier Fernández‐Calvo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Javier Fernández‐Calvo. Javier Fernández‐Calvo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
García‐Sánz, Ramón, Enrique M. Ocio, Lucía López‐Anglada, et al.. (2011). Post-Treatment Bone Marrow Residual Disease > 5% by Flow Cytometry Is Highly Predictive of Short Progression-Free and Overall Survival in Patients With Waldenström's Macroglobulinemia. Clinical Lymphoma Myeloma & Leukemia. 11(1). 168–171. 8 indexed citations
2.
Sarasquete, María Eugenia, Ramón García‐Sánz, Carmen Chillón, et al.. (2008). Low expression of ZHX2, but not RCBTB2 or RAN, is associated with poor outcome in multiple myeloma. British Journal of Haematology. 141(2). 212–215. 28 indexed citations
3.
Xicoy, Blanca, Josep‐María Ribera, Albert Oriol, et al.. (2006). Significado pronóstico de los subtipos inmunológicos de la leucemia aguda linfoblástica T del adulto. Estudio de 81 pacientes. Medicina Clínica. 126(2). 41–46. 2 indexed citations
4.
García‐Sánz, Ramón, Joan Bladé, Javier Fernández‐Calvo, et al.. (2004). Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma. British Journal of Haematology. 127(2). 159–164. 53 indexed citations
5.
6.
Chillón, Carmen, Ramón García‐Sánz, Ana Balanzategui, et al.. (2004). FLT3-activating mutations are associated with poor prognostic features in AML at diagnosis but they are not an independent prognostic factor. The Hematology Journal. 5(3). 239–246. 25 indexed citations
7.
García‐Sánz, Ramón, Jesús María Hernández‐Rivas, M C López-Berges, et al.. (2004). Proliferative activity of plasma cells is the most relevant prognostic factor in elderly multiple myeloma patients. International Journal of Cancer. 112(5). 884–889. 36 indexed citations
8.
Martı́n, Alejandro, Ramón García‐Sánz, José‐Ángel Hernández‐Rivas, et al.. (2002). Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti‐tumour effect. British Journal of Haematology. 118(1). 239–242. 52 indexed citations
9.
Mateos, María‐Victoria, Ramón García‐Sánz, Ricardo López‐Pérez, et al.. (2002). Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival. British Journal of Haematology. 118(4). 1034–1040. 63 indexed citations
10.
Miguel, Jesús F. San, Júlia Almeida, Gema Mateo, et al.. (2002). Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome. Blood. 99(5). 1853–1856. 99 indexed citations
11.
Mateos, María‐Victoria, Ramón García‐Sánz, Ricardo López‐Pérez, et al.. (2001). p16/INK4a gene inactivation by hypermethylation is associated with aggressive variants of monoclonal gammopathies. The Hematology Journal. 2(3). 146–149. 23 indexed citations
12.
Chillón, Carmen, Ramón García‐Sánz, Ana Balanzategui, et al.. (2001). Molecular characterization of acute myeloblastic leukemia according to the new WHO classification: a different distribution in Central-West Spain.. PubMed. 86(2). 162–6. 11 indexed citations
13.
García‐Sánz, Ramón, Marcos González, María Dolores Tabernero, et al.. (1999). Primary Plasma Cell Leukemia: Clinical, Immunophenotypic, DNA Ploidy, and Cytogenetic Characteristics. Blood. 93(3). 1032–1037. 212 indexed citations
14.
Pérez-Simón, Josè Antonio, Ramón García‐Sánz, María Dolores Tabernero, et al.. (1998). Prognostic Value of Numerical Chromosome Aberrations in Multiple Myeloma: A FISH Analysis of 15 Different Chromosomes. Blood. 91(9). 3366–3371. 127 indexed citations
15.
Pérez-Simón, Josè Antonio, Ramón García‐Sánz, María Dolores Tabernero, et al.. (1998). Prognostic Value of Numerical Chromosome Aberrations in Multiple Myeloma: A FISH Analysis of 15 Different Chromosomes. Blood. 91(9). 3366–3371. 3 indexed citations
16.
Miguel, Jesús F. San, Antonio Rodríguez Martínez, Antônio Vaz de Macedo, et al.. (1997). Immunophenotyping Investigation of Minimal Residual Disease Is a Useful Approach for Predicting Relapse in Acute Myeloid Leukemia Patients. Blood. 90(6). 2465–2470. 209 indexed citations
17.
Miguel, Jesús F. San, Antonio Rodríguez Martínez, Antônio Vaz de Macedo, et al.. (1997). Immunophenotyping Investigation of Minimal Residual Disease Is a Useful Approach for Predicting Relapse in Acute Myeloid Leukemia Patients. Blood. 90(6). 2465–2470. 9 indexed citations
18.
Macedo, Antônio Vaz de, Alberto Órfão, María‐Belén Vídriales, et al.. (1995). Characterization of aberrant phenotypes in acute myeloblastic leukemia. Annals of Hematology. 70(4). 189–194. 73 indexed citations
19.
González, Marcos, et al.. (1987). Surface phenotype and clinical stages in B-cell chronic lymphocytic leukaemia.. PubMed. 72(1). 39–43. 4 indexed citations
20.
Fernández‐Calvo, Javier, et al.. (1977). Seroepidemiology of the poliovirus in Monrovia (Liberia). Transactions of the Royal Society of Tropical Medicine and Hygiene. 71(2). 118–126. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Richard E. Helmer Breakdown of academic impact, for papers by Hakumei Oh Breakdown of academic impact, for papers by Fen‐Yu Lee Breakdown of academic impact, for papers by Kiyotaka Kashima Breakdown of academic impact, for papers by Dieter K. Hossfeld Breakdown of academic impact, for papers by Sylvie Ramond Breakdown of academic impact, for papers by Joseph O. Moore Breakdown of academic impact, for papers by Najla H. Al Ali Breakdown of academic impact, for papers by JR Testa Breakdown of academic impact, for papers by CM Rubin
Rankless by CCL
2026